Loading clinical trials...
Loading clinical trials...
A Phase II Study Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-Mediated Cytopenias
Conditions
Interventions
fostamatinib
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
March 10, 2023
Primary Completion Date
June 16, 2023
Completion Date
June 16, 2023
Last Updated
December 5, 2025
NCT02611180
NCT04294641
NCT05509582
NCT04146207
NCT02519816
NCT01106833
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions